Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups

Francesco Passiglia, Antonio Galvano, Valerio Gristina, Nadia Barraco, Marta Castiglia, Alessandro Perez, Maria La Mantia, Antonio Russo, Viviana Bazan